CRA Clinical Research Associate - Clinical Research Associate Merck Employee Review

1.0
Jun 23, 2018
Recommend
CEO approval
Business Outlook

Pros

Great pay, great benefits, pension plan.

Cons

I worked at CROs for over 10 years and decided to try pharma as Merck was builiding its own oncology clinical teams and I believed that it would be an exiting time to join the company. Merck is new to oncology and the middle managers don't understand the complexity of oncology trials. I was assigned to so many sites and different protocols, that it was hard to keep up, even if with working 60-80 hours a week. I worried about the quality of the research, as systems were very old and the way of conducting the research was old as well. Sites I took over from other CRAs had huge data backlog. Instead of managing the sites and doing quality research, I was reviewing data from the past months and was resolving old issues. I brought this to the attention of my manager, and what bothered me the most was indifference. The supervisor of the managers had the same attitude and during the calls was more concerned about keeping the agenda than answering questions from the CRAs. This is the company where the CRAs were treated with the least respect. I left the company in less than a year. Quality of the research was my main concern.

Explore other reviews about Merck

5.0
Apr 10, 2026
Recommend
CEO approval
Business Outlook

Pros

Great work life balance and benefits

Cons

Layoffs are ongoing with patent cliff

2.0
Nov 5, 2025
Recommend
CEO approval
Business Outlook

Pros

Genuinely nice people trying to do their best to help patients and advance science. It's a good spot if you're early career with generous vacation allowance and opportunity to learn as long as you don't get sucked up in the politics and bureaucracy. The closer you get to the EDs and VPs, the more it stinks.

Cons

Share price is in the toilet and the sales are down so even though the pipeline is strong, it's going to be a tough 3-5yrs as they try to get sales back up to replace Keytruda revenue. Massive cost cutting efforts ongoing and stealth offshoring of IT jobs is the current activity to appease the markets. There's real issues with burnout as the senior leaders turn the screw for productivity and there's no support other than words and stupid initiatives that only bring more work to do. Merck are leaking talent at mid to senior level because they are fed up with being unsupported meanwhile the divisional leaders are all slapping themselves on the back because they did something pointless with AI (the data 'lake' is still a putrid swamp). Too many of the leadership have been there too long and seem to be rewarded for mediocrity and boot licking. Recent promotions are the wrong ones and seem to be developing a 'bro' culture. Very unappealing but we all know DEI is not taken seriously these days so I'm not expecting any action there. Overall, the leadership is out of touch, ineffective and totally unable to set a direction and stick to it.

2
See reviews by: Helpful|Rating|Date|All